- Home
- LUNR vs JANX Comparison
LUNR vs JANX Comparison
Compare LUNR & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNR
- JANX
- Stock Information
- Founded
- LUNR 2013
- JANX 2017
- Country
- LUNR United States
- JANX United States
- Employees
- LUNR N/A
- JANX N/A
- Industry
- LUNR Industrial Machinery/Components
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- LUNR Industrials
- JANX Health Care
- Exchange
- LUNR Nasdaq
- JANX Nasdaq
- Market Cap
- LUNR 1.3B
- JANX 1.4B
- IPO Year
- LUNR N/A
- JANX 2021
- Fundamental
- Price
- LUNR $10.74
- JANX $24.88
- Analyst Decision
- LUNR Buy
- JANX Strong Buy
- Analyst Count
- LUNR 7
- JANX 7
- Target Price
- LUNR $15.21
- JANX $94.29
- AVG Volume (30 Days)
- LUNR 6.3M
- JANX 658.5K
- Earning Date
- LUNR 08-12-2025
- JANX 08-06-2025
- Dividend Yield
- LUNR N/A
- JANX N/A
- EPS Growth
- LUNR N/A
- JANX N/A
- EPS
- LUNR N/A
- JANX N/A
- Revenue
- LUNR $217,305,000.00
- JANX $9,336,000.00
- Revenue This Year
- LUNR $20.66
- JANX N/A
- Revenue Next Year
- LUNR $45.85
- JANX $1,470.82
- P/E Ratio
- LUNR N/A
- JANX N/A
- Revenue Growth
- LUNR 61.52
- JANX 28.12
- 52 Week Low
- LUNR $3.15
- JANX $22.48
- 52 Week High
- LUNR $24.95
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- LUNR 50.90
- JANX 50.75
- Support Level
- LUNR $10.44
- JANX $22.74
- Resistance Level
- LUNR $11.52
- JANX $24.73
- Average True Range (ATR)
- LUNR 0.61
- JANX 1.25
- MACD
- LUNR -0.01
- JANX 0.16
- Stochastic Oscillator
- LUNR 63.56
- JANX 60.44
About LUNR Intuitive Machines Inc.
Intuitive Machines Inc is a space exploration, infrastructure, and services company. It is a diversified space company focused on space exploration. It supplies space products and services to support sustained robotic and human exploration to the Moon, Mars, and beyond. Its products and services are offered through its four business units: Lunar Access Services, Orbital Services, Lunar Data Services, and Space Products and Infrastructure. The Company operates in one operating segment and one reportable segment underpinned by three core pillars (delivery services, data transmission services, and infrastructure as a service) that have similar capabilities, customers, and economic characteristics. Revenue is from contracts with customers of orbital and lunar access services.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.